- Home
- FNWB vs IKNA Comparison
FNWB vs IKNA Comparison
Compare FNWB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWB
- IKNA
- Stock Information
- Founded
- FNWB 1923
- IKNA 2016
- Country
- FNWB United States
- IKNA United States
- Employees
- FNWB N/A
- IKNA N/A
- Industry
- FNWB Banks
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- FNWB Finance
- IKNA Health Care
- Exchange
- FNWB Nasdaq
- IKNA Nasdaq
- Market Cap
- FNWB 79.5M
- IKNA 63.7M
- IPO Year
- FNWB 2015
- IKNA 2021
- Fundamental
- Price
- FNWB $8.00
- IKNA $1.43
- Analyst Decision
- FNWB Hold
- IKNA Strong Buy
- Analyst Count
- FNWB 1
- IKNA 1
- Target Price
- FNWB $12.00
- IKNA $4.00
- AVG Volume (30 Days)
- FNWB 47.9K
- IKNA 105.8K
- Earning Date
- FNWB 07-24-2025
- IKNA 08-07-2025
- Dividend Yield
- FNWB 3.37%
- IKNA N/A
- EPS Growth
- FNWB N/A
- IKNA N/A
- EPS
- FNWB N/A
- IKNA N/A
- Revenue
- FNWB $45,593,000.00
- IKNA N/A
- Revenue This Year
- FNWB $38.07
- IKNA N/A
- Revenue Next Year
- FNWB $13.28
- IKNA N/A
- P/E Ratio
- FNWB N/A
- IKNA N/A
- Revenue Growth
- FNWB N/A
- IKNA N/A
- 52 Week Low
- FNWB $6.05
- IKNA $0.97
- 52 Week High
- FNWB $12.10
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- FNWB 47.16
- IKNA 56.42
- Support Level
- FNWB $7.85
- IKNA $1.33
- Resistance Level
- FNWB $8.31
- IKNA $1.43
- Average True Range (ATR)
- FNWB 0.48
- IKNA 0.05
- MACD
- FNWB 0.10
- IKNA -0.00
- Stochastic Oscillator
- FNWB 68.66
- IKNA 59.91
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.